Keywords: Orexo, Boehringer Ingelheim, Pain, Inflammatory diseases, Milestone

Orexo gets $8.6 million milestone in Boehringer Ingelheim collaboration

Article | 17 December 2010

Print This

Sweden’s Orexo AB (STO: ORX) says that independent German drugmaker Boehringer Ingelheim has selected a development candidate resulting ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in